NASDAQ:CLSD Clearside Biomedical Q2 2024 Earnings Report ProfileEarnings HistoryForecast Clearside Biomedical EPS ResultsActual EPS-$1.50Consensus EPS -$2.10Beat/MissBeat by +$0.60One Year Ago EPS-$2.25Clearside Biomedical Revenue ResultsActual Revenue$0.09 millionExpected Revenue$0.25 millionBeat/MissMissed by -$160.00 thousandYoY Revenue GrowthN/AClearside Biomedical Announcement DetailsQuarterQ2 2024Date8/12/2024TimeAfter Market ClosesConference Call DateMonday, August 12, 2024Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Clearside Biomedical Earnings HeadlinesClearside Biomedical Faces Delisting After Bankruptcy FilingNovember 25, 2025 | msn.comClearside Biomedical to pursue sale of business via Chapter 11 processNovember 24, 2025 | msn.comSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.July 5 at 1:00 AM | TradeSmith (Ad)Clearside Biomedical, Inc. Files Chapter 11 Bankruptcy to Pursue Asset Sale and Maximize Stakeholder ValueNovember 24, 2025 | quiverquant.comQClearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 ProcessNovember 24, 2025 | globenewswire.comClearside Biomedical Regains Nasdaq Compliance as of October 2025October 7, 2025 | tipranks.comSee More Clearside Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email. Email Address About Clearside BiomedicalClearside Biomedical (NASDAQ:CLSD) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for diseases affecting the back of the eye. The company’s proprietary SCS Microinjector® platform enables targeted delivery of therapeutics into the suprachoroidal space, a potential route to enhance local drug exposure while minimizing off-target effects. Clearside’s approach is designed to address a range of retinal disorders by directly depositing medication adjacent to choroid and retina. The company’s lead approved product is XIPERE® (triamcinolone acetonide injectable suspension), which has received U.S. Food and Drug Administration clearance for the treatment of macular edema associated with uveitis. In addition to XIPERE, Clearside has advanced several pipeline candidates, including CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration and other small-molecule and biologic programs leveraging the suprachoroidal route. These programs are in various stages of clinical development, targeting indications such as diabetic macular edema and wet AMD. Founded in 2010 and headquartered in Alpharetta, Georgia, Clearside Biomedical completed its initial public offering on the Nasdaq Stock Market under the ticker “CLSD.” The company is led by President and Chief Executive Officer Samir Melhem, who has overseen clinical and regulatory milestones, including FDA approval of XIPERE. Clearside continues to explore both U.S. and ex-U.S. partnerships to expand patient access to its suprachoroidal therapies.View Clearside Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
